Isos Pharmacorp, S.A. de C.V.

Mexico City, Mexico City 06700

0 studies enrolling now · 1 studies all time

What they study most

Follicular Lymphoma

Studies at this site

• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed